Wall Street Analysts Are Neutral on Top Healthcare Picks
Analysts fell to the sidelines weighing in on Alkermes (ALKS), Apellis Pharmaceuticals (APLS) and Kalaris Therapeutics (KLRS) with neutral ratings, indicating that the experts are neither bullish nor bearish on the stocks.
End of Quarter Sale - 50% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Alkermes (ALKS)
Leerink Partners analyst Marc Goodman maintained a Hold rating on Alkermes today. The company’s shares closed last Tuesday at $36.03, close to its 52-week high of $36.45.
According to TipRanks.com, Goodman is ranked #343 out of 12128 analysts.
Alkermes has an analyst consensus of Strong Buy, with a price target consensus of $44.00, representing a 33.5% upside. In a report issued on March 20, TipRanks – Google also downgraded the stock to Hold with a $30.00 price target.
See today’s best-performing stocks on TipRanks >>
Apellis Pharmaceuticals (APLS)
In a report released today, Akash Tewari from Jefferies downgraded Apellis Pharmaceuticals to Hold, with a price target of $41.00. The company’s shares closed last Tuesday at $40.26.
According to TipRanks.com, Tewari is a 5-star analyst with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Moderate Buy with an average price target of $34.12, representing a -15.5% downside. In a report released today, Robert W. Baird also downgraded the stock to Hold with a $41.00 price target.
Kalaris Therapeutics (KLRS)
In a report released yesterday, Biren Amin from Piper Sandler maintained a Hold rating on Kalaris Therapeutics, with a price target of $7.00. The company’s shares closed last Tuesday at $5.84.
According to TipRanks.com, Amin is a 4-star analyst with an average return of
Currently, the analyst consensus on Kalaris Therapeutics is a Moderate Buy with an average price target of $7.91, a 50.7% upside from current levels. In a report issued on March 19, TipRanks – OpenAI also reiterated a Hold rating on the stock with a $7.50 price target.
Read More on ALKS:
